Drugs /

eganelisib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, IPI-549 prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.

Clinical Trials

View Clinical Trials for eganelisib

Eganelisib has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating eganelisib, 2 are phase 1 (2 open) and 3 are phase 2 (3 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for eganelisib clinical trials.

Breast carcinoma, bladder urothelial carcinoma, and carcinoma are the most common diseases being investigated in eganelisib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Eganelisib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating eganelisib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ipi 549, pi3k-gamma inhibitor ipi-549, ipi-549
Drug Categories [2]:
PI3K inhibitors
Drug Target(s) [2]:
PIK3CG
NCIT ID [1]:
C125471

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.